Effects of Low-Fat, Mediterranean, or Low-Carbohydrate Weight Loss Diets on Serum Urate and Cardiometabolic Risk Factors - A Secondary Analysis of the Dietary Intervention Randomized Controlled Trial (DIRECT)
posted on 2020-09-02, 20:56authored byChio Yokose, Natalie McCormick, Sharan K. Rai, Na Lu, Gary Curhan, Dan Schwarzfuchs, Iris Shai, Hyon K. Choi
Objectives: <a>Weight loss
diets may reduce serum urate (SU) by lowering insulin resistance while
providing cardiometabolic benefits, something urate-lowering drugs have not
shown in trials. </a>We aim to examine the effects of weight loss
diets on SU and cardiometabolic risk factors.
<p>Research Design and
Methods: Secondary study of the Dietary Intervention Randomized Controlled
Trial (DIRECT) using stored samples from 235 participants with moderate obesity
randomly assigned to low-fat, restricted-calorie (n=85), Mediterranean,
restricted-calorie (n=76), or low-carbohydrate, non-restricted-calorie (n=74)
diets. We examined SU changes at 6- and 24-months overall, and among those with
hyperuricemia (SU³416 μmol/L), a relevant subgroup at risk for
gout.</p>
<p>Results: Among all
participants, average SU decreases were 48 μmol/L at 6-months and 18 μmol/L at
24-months, with no differences between diets (p>0.05). Body weight, HDL-C,
total cholesterol to HDL-C ratio, triglycerides, and insulin concentrations also
improved in all three groups (p<0.05 at 6 months). Adjusting for covariates,
changes in weight and fasting plasma insulin concentrations remained associated
with SU changes (p<0.05). SU reductions among those with hyperuricemia were 113,
119, and 143 μmol/L at 6 months for low-fat, Mediterranean, and
low-carbohydrate diets (all p for within-group comparison <0.001; p>0.05
for between-group comparisons), and 65, 77, and 83 μmol/L, respectively, at
24-months (all p for within-group comparison <0.01; p>0.05 for
between-group comparisons).</p>
<a>Conclusions</a>: <a>Non-purine-focused
weight loss diets may simultaneously improve SU and cardiovascular risk factors, likely mediated by
reducing adiposity and insulin resistance. </a>These dietary options could provide personalized pathways to suit
patient comorbidity and preferences for adherence.
Funding
This study was supported by the National Institutes of Health [P50 AR060772 and R01 AR065944]. CY is supported by the National Institutes of Health Ruth L. Kirschstein Institutional National Research Service Award [T32 AR007258]. NM is supported by a Fellowship Award from the Canadian Institutes of Health Research. SR is supported by a Doctoral Foreign Study Award from the Canadian Institutes of Health Research. GC is supported by the National Institutes of Health [K24 DK091417].IS is supported by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) SFB 1052 and the Israeli Science Foundation and Israel Ministry of Science and Technology.